GSK plc announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent… read more.
Eli Lilly and Company announced that the FDA has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved… read more.
A collaborative research group led by Professor Kenjiro Ono of the Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, and Eisai Co., Ltd., used a newly developed… read more.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Jeraygo (aprocitentan) to treat hypertension (high blood pressure) in adults whose blood pressure cannot be adequately controlled… read more.
Novo Nordisk announced headline results from STEP UP, a phase IIIb trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous… read more.
Boston Scientific Corporation (announced data supporting the use of the FARAPULSE Pulsed Field Ablation (PFA) System during a late-breaking science session at AF Symposium 2025. Currently, the FARAPULSE… read more.
Bayer announced the submission of marketing authorization applications to the FDA and to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), seeking approval… read more.
Roche announced that the European Medicines Agency has approved Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet’ age-related macular… read more.
GSK plc announced that the FDA has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) for the prevention… read more.
NICE (UK): 1.1 Tebentafusp is recommended, within its marketing authorisation, for treating HLA‑A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company provides… read more.
Verona Pharma plc announces preliminary unaudited net product sales for the fourth quarter and full year ended December 31, 2024, and provides a corporate update. “2024 was another… read more.
Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia (defatted powder of Arachis hypogaea L.,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
